The article 🌱 Patch AM: How a Gaithersburg student is earning a biotech degree without debt appeared first on Gaithersburg ...

AstraZeneca and Daiichi Sankyo got U.S. approval to expand the label of their jointly developed Enhertu drug in combination with another medicine as an initial treatment for a type of breast cancer.

Investing.com -- AstraZeneca (NASDAQ:AZN) said on Tuesday it has received European Union approval for Saphnelo (anifrolumab) ...

Sanofi and AstraZeneca’s Beyfortus (Nirsevimab) is now approved by the National Pharmaceutical Regulatory Agency (NPRA) and ...

In the latest close session, Astrazeneca (AZN) was up +1.93% at $91.56. The stock's change was more than the S&P 500's daily loss of 0.16%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq ...

The FDA's approval is based on results from the Phase III DESTINY-Breast09 trial, in which the combo showed a median 40.7-month progression-free survival.

Food and Drug ​Administration has approved ‌Daiichi Sankyo's therapy in combination ‌with Roche's drug for the first-line ...

After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...

RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...

England has embraced degree apprenticeship as a solution to a wide range of challenges, including high youth unemployment, spiraling student debt and rapid technological change. The programs have been ...

A group of eight Democratic senators is asking biopharma companies to spill the beans about their private most-favored-nation pricing deals with U.S. President Donald Trump. Led by Sen. Ron Wyden, ...

In this video, Brian T. Hill, MD, PhD, discusses data from the Smart Stop trial assessing the effects of a novel targeted combination therapy in patients with newly diagnosed diffuse large B-cell ...